Physician profile
Christopher Loynd
NPI 1003965955
$265,198.16
in general payments reported to CMS, 2019-2025
23 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $11K · 2021: $12K · 2022: $23K · 2023: $58K · 2024: $51K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $159K · Travel and Lodging: $20K · Food and Beverage: $7,312 · Consulting Fee: $5,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $159,400.00 |
| Travel and Lodging | $19,985.94 |
| Food and Beverage | $7,312.23 |
| Consulting Fee | $5,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $222,702.35 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30,072.92 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $8,947.86 | 2019-2020 | |
| Alkermes, INC. | $785.50 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $657.69 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $317.14 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $288.70 | 2019-2025 | Ingrezza |
| Allergan, INC. | $231.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.28 | 2019-2025 | Trintellix |
| Abbvie INC. | $179.38 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $159.04 | 2019-2025 | Fanapt |
| Luye Pharma (USA) Ltd. | $137.39 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $136.73 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $111.12 | 2024 | Farxiga |
| Axsome Therapeutics, INC. | $52.74 | 2024-2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.99 | 2025 | Cobenfy |
| Lundbeck LLC | $30.22 | 2023-2024 | Rexulti |
| Almatica Pharma LLC | $28.98 | 2024-2025 | Loreev Xr |
| Hologic Sales and Service, LLC | $21.58 | 2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Noven Therapeutics, LLC | $19.33 | 2020 | |
| Bausch Health US, LLC | $19.07 | 2022 | |
| Indivior INC. | $18.30 | 2022 | |
| Shire North American Group INC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Loynd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.